The most recognized two-peptide injury recovery stack in research peptide communities. BPC-157 and TB-500 pre-blended in a single vial — complementary mechanisms, one injection.
BPC-157 and TB-500 became the canonical injury recovery stack because they work through distinct but synergistic pathways — and because the combination has more community-verified protocol history than any other peptide pairing. BPC-157 operates through receptor-mediated local signaling; TB-500 drives systemic cell migration and angiogenesis. Together they create a healing environment at the injury site that neither achieves alone.
The Wolverine blend pre-mixes both at equal 10mg doses — eliminating the need for two separate reconstitutions, two separate calculations, and careful combining before each injection. One vial, one draw, done.
The most studied application for this stack. BPC-157 stimulates tendon fibroblast proliferation at the injury site; TB-500 recruits repair cells through actin-mediated migration and brings new blood vessel formation from all directions.
BPC-157's NO and VEGFR2 pathways support muscle fiber healing; TB-500 drives satellite cell migration into damaged muscle and supports angiogenesis for improved oxygen delivery during repair.
BPC-157 builds blood vessels through VEGFR2; TB-500 builds them through cell migration and actin remodeling. Two independent angiogenic pathways active simultaneously — richer vascular environment at the healing site.
Both peptides reduce local and systemic inflammation through different mechanisms — BPC-157 through NO and growth factor modulation, TB-500 through cytokine and actin pathway effects.
Research models show both peptides support joint tissue integrity — BPC-157 through local receptor signaling, TB-500 through cell migration and angiogenesis into avascular cartilage regions.
Two peptides, one vial. No mixing ratio calculations. No double reconstitution. Equal 10mg doses of each component — the most common ratio used in research community protocols.
Wolverine is available in two vial sizes — choose based on your cycle length and dosing frequency.
BPC-157: 10mg | TB-500: 10mg per vial. Full-dose protocol. Most common research choice. Enough for approximately 10–20 injections depending on reconstitution volume and dose drawn.
BPC-157: 5mg | TB-500: 5mg per vial. Lower-dose protocol or introductory run. Same 1:1 ratio. Suitable for maintenance cycles or researchers who prefer lower starting doses.
| Parameter | Detail |
|---|---|
| Reconstitution | Add 1–2 mL bacteriostatic water gently to lyophilized powder |
| Frequency | Once daily or every other day during loading; 2–3x per week maintenance |
| Route | Subcutaneous — abdomen, upper thigh, or near injury site |
| Loading Phase | Daily or every other day for 4–6 weeks |
| Maintenance | 2–3x per week for 4–8 additional weeks |
| Storage (reconstituted) | Refrigerate; use within 30 days |
Wolverine is the entry point — the proven two-peptide recovery stack. GLOW adds GHK-Cu for collagen synthesis and skin regeneration. KLOW adds KPV for gut and inflammation focus. All share the BPC-157 + TB-500 core.
Wolverine is a pre-blended peptide combination sold for research purposes only. Neither BPC-157 nor TB-500 are FDA-approved drugs. The information on this page is educational and does not constitute medical advice. Consult a qualified healthcare professional before any peptide protocol.
Pre-blended. Dual-analyte COA. Finnrick Analytics verified. Ships within 24 hours.
Get Started Today